Akari Therapeutics updates corporate presentation on bi-functional ADC pipeline

Akari Therapeutics Plc

Updated slide deck highlights next-generation precision bi-functional antibody drug conjugate platform.
Presentation dated January 2025 to be used in meetings with investors and potential partners.
No new financial guidance, clinical data, or operational milestones disclosed in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.